JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA.
Antimicrob Agents Chemother. 2011 Nov;55(11):5155-8. doi: 10.1128/AAC.00570-11. Epub 2011 Aug 15.
E1210 is a first-in-class broad-spectrum antifungal that suppresses hyphal growth by inhibiting fungal glycophosphatidylinositol (GPI) biosynthesis. In the present study, we extend these findings by examining the activity of E1210 and comparator antifungal agents against Aspergillus spp. by using the methods of the Clinical and Laboratory Standards Institute (CLSI) and the European Committee for Antimicrobial Susceptibility Testing (EUCAST) to test wild-type (WT) as well as amphotericin B (AMB)-resistant (-R) and azole-R strains (as determined by CLSI methods). Seventy-eight clinical isolates of Aspergillus were tested including 20 isolates of Aspergillus flavus species complex (SC), 22 of A. fumigatus SC, 13 of A. niger SC, and 23 of A. terreus SC. The collection included 15 AMB-R (MIC, ≥ 2 μg/ml) isolates of A. terreus SC and 10 itraconazole-R (MIC, ≥ 4 μg/ml) isolates of A. fumigatus SC (7 isolates), A. niger SC (2 isolates), and A. terreus SC (1 isolate). Comparator antifungal agents included anidulafungin, caspofungin, amphotericin B, itraconazole, posaconzole, and voriconazole. Both CLSI and EUCAST methods were highly concordant for E1210 and all comparators. The essential agreement (EA; ± 2 log(2) dilution steps) was 100% for all comparisons with the exception of posaconazole versus A. terreus SC (EA = 91.3%). The minimum effective concentration (MEC)/MIC(90) values (μg/ml) for E1210, anidulafungin, caspofungin, itraconazole, posaconazole, and voriconazole, respectively, were as follows for each species: for A. flavus SC, 0.03, ≤ 0.008, 0.12, 1, 1, and 1; for A. fumigatus SC, 0.06, 0.015, 0.12, >8, 1, and 4; for A. niger SC, 0.015, 0.03, 0.12, 4, 1, and 2; and for A. terreus SC, 0.06, 0.015, 0.12, 1, 0.5, and 1. E1210 was very active against AMB-R strains of A. terreus SC (MEC range, 0.015 to 0.06 μg/ml) and itraconazole-R strains of A. fumigatus SC (MEC range, 0.03 to 0.12 μg/ml), A. niger SC (MEC, 0.008 μg/ml), and A. terreus SC (MEC, 0.015 μg/ml). In conclusion, E1210 was a very potent and broad-spectrum antifungal agent regardless of in vitro method applied, with excellent activity against AMB-R and itraconazole-R strains of Aspergillus spp.
E1210 是一种首创的广谱抗真菌药物,通过抑制真菌糖基磷脂酰肌醇(GPI)生物合成来抑制菌丝生长。在本研究中,我们通过使用临床和实验室标准研究所(CLSI)和欧洲抗菌药物敏感性测试委员会(EUCAST)的方法,对 E1210 和比较抗真菌药物对曲霉属的活性进行了扩展研究,以测试野生型(WT)以及两性霉素 B(AMB)耐药(-R)和唑类耐药(-R)菌株(通过 CLSI 方法确定)。测试了 78 株临床分离的曲霉属,包括 20 株黄曲霉属种复合物(SC)、22 株烟曲霉属 SC、13 株黑曲霉属 SC 和 23 株土曲霉属 SC。该集合包括 15 株 AMB-R(MIC,≥2μg/ml)的土曲霉属 SC 和 10 株伊曲康唑-R(MIC,≥4μg/ml)的烟曲霉属 SC(7 株)、黑曲霉属 SC(2 株)和土曲霉属 SC(1 株)。比较抗真菌药物包括安尼伐单抗、卡泊芬净、两性霉素 B、伊曲康唑、泊沙康唑和伏立康唑。E1210 和所有比较剂的 CLSI 和 EUCAST 方法均高度一致。除泊沙康唑与土曲霉属 SC(EA=91.3%)外,所有比较的基本协议(EA;±2 对数稀释度)均为 100%。E1210、安尼伐单抗、卡泊芬净、伊曲康唑、泊沙康唑和伏立康唑的最小有效浓度(MEC)/MIC(90)值(μg/ml)分别为:黄曲霉属 SC,0.03、≤0.008、0.12、1、1 和 1;烟曲霉属 SC,0.06、0.015、0.12、>8、1 和 4;黑曲霉属 SC,0.015、0.03、0.12、4、1 和 2;土曲霉属 SC,0.06、0.015、0.12、1、0.5 和 1。E1210 对 AMB-R 土曲霉属 SC 菌株(MEC 范围,0.015 至 0.06μg/ml)和伊曲康唑-R 烟曲霉属 SC 菌株(MEC 范围,0.03 至 0.12μg/ml)、黑曲霉属 SC(MEC,0.008μg/ml)和土曲霉属 SC(MEC,0.015μg/ml)非常有效。总之,E1210 是一种非常有效且广谱的抗真菌药物,无论应用何种体外方法,对 AMB-R 和伊曲康唑-R 的曲霉属菌株均具有极好的活性。